Italy Launches Major Study to Track Type 1 Diabetes Before Symptoms Appear

Type 1 diabetes doesn't appear overnight. Scientists know the disease develops through recognizable stages—beginning with autoantibodies (immune markers) that can be detected years before any symptoms. A new Italian law, Law 130/2023, mandates screening for these early warning signs in the general population, creating an unprecedented opportunity to study disease progression.

The SIRENA study—which stands for Standardized Italian netwoRk Enrolling iNdividuals with islet-Autoantibodies—is the research response to this mandate. Launched by the Italian Society for Pediatric Endocrinology and Diabetology and coordinated across more than 40 centers nationwide, SIRENA will enroll and follow asymptomatic children and adults who carry at least one confirmed islet autoantibody.

Over the next 10 years, SIRENA researchers will collect detailed clinical, biochemical, immunological, and patient-reported data from study participants. The primary focus is understanding who progresses to clinical Type 1 diabetes and when.

Secondary goals include distinguishing between two forms of onset—biochemical (detectable through lab tests) and symptomatic (with noticeable signs like thirst and fatigue)—and measuring how often diabetic ketoacidosis (DKA), a dangerous complication, occurs at diagnosis. By mapping these disease trajectories in real time, researchers hope to identify patterns that predict progression and severity.

One key strength of SIRENA is its standardized data collection. All information will be entered into a central electronic database aligned with international standards, allowing the study to feed into the European pre-T1D Registry. This means Italian findings will contribute to a continent-wide understanding of presymptomatic Type 1 diabetes.

Perhaps most importantly, structured follow-up of people at risk creates a practical pathway to emerging interventions. Therapies like teplizumab, which can delay the onset of Type 1 diabetes, require early identification of candidates. SIRENA's design makes such enrollment more efficient and systematic than ad hoc detection alone.

Knowing you carry autoantibodies—before diabetes symptoms develop—offers a window of opportunity. Early, structured follow-up reduces the shock of diagnosis and the risk of dangerous complications like DKA at onset. It also gives families and clinicians time to plan, prepare, and explore whether new preventive treatments might be a fit.

SIRENA represents a shift from waiting for symptoms to actively monitoring those at risk. By enrolling thousands across Italy and sharing data globally, the study aims to deepen our understanding of who develops Type 1 diabetes, when, and how—knowledge that could reshape prevention strategies for decades to come.

Source: BMJ open. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.